Salman et al. (2019) developed third-generation CD4-specific CAR-T cells and CD4 CAR-NK cells, since CD4 is expressed in some AML subtypes, as a strategy to eradicate CD4+ residual AML before transplant. Here, CD4 is linked to acute myeloid leukemia.